Slide 1: Fiscal Second Quarter 2026 Financial Results
Fiscal Second Quarter 2026 Financial Results EARNINGS PRESENTATION May 6, 2026 © 2026 Azenta, Inc. • All rights reserved
Slide 2: Safe Harbor Statement
Safe Harbor Statement Safe Harbor Statement This presentation contains “forward looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward looking statements include, without limitation, statements regarding future financial performance and outlook,
Slide 3: Azenta Life Sciences Q2 2026 Financial Overview
Azenta Life Sciences Q2 2026 Financial Overview QUARTER ENDED MARCH 31, 2026 Performance Highlights Adjusted Revenue Q2’26 Revenue EBITDA Margin • Revenue $145M, up 1% reported and down 3% organic YoY • Multiomics down 2% from lower volumes in North America $145M 5% • SMS down 3% from softer demand
Slide 4: Q2 2026 Selected Non-GAAP Financial Measures
Q2 2026 Selected Non-GAAP Financial Measures QUARTER ENDED MARCH 31, 2026 Total Azenta Organic Growth $ millions except EPS and percentages Non-GAAP $ millions Q2'25 Q2'26 YtY Revenue $ 143 $ 145 1% Q2’25 Q2’26 YtY Gross profit $ 65 64 (1%) % 45.4% 44.3% (1.1) pts. Reported 143 145 1% R&D 8 9 24% FX
Slide 5: Q2 2026 Performance by Segment
Q2 2026 Performance by Segment ORGANIC UNLESS OTHERWISE NOTED Revenue by Segment Sample Management Solutions (“SMS”) • LDD decline in Core Products due to prolonged 44% softness in Automated and Cryogenic Stores Multiomics (GENEWIZ) • LSD growth in Consumables and • $64 million Instruments • Flat Yo
Slide 6: Summary Consolidated Balance Sheet
Summary Consolidated Balance Sheet QUARTER ENDED MARCH 31, 2026 Balance Sheet $ millions Dec Mar 2025 2026 QtQ Cash, restricted cash, short term marketable securities 412 383 (29) Accounts receivable, net 142 131 (11) • $574M of cash, cash equivalents, restricted Inventories 82 79 (4) cash and marke
Slide 7: Summary Consolidated Cash Flow
Summary Consolidated Cash Flow QUARTER ENDED MARCH 31, 2026 Cash Flow $ millions Q2'26 Cash, restricted cash and marketable securities - Beginning 581 • $574M cash, cash equivalents, restricted Net income (161) cash and marketable securities, including Non-cash adjustments 154 $9M of cash in Current
Slide 8: Fiscal Year 2026 Guidance
Fiscal FiscalYear Year2026 2024Guidance Guidance 2026 Guidance Prior (November 2025) Updated (May 2026) Comments • Low end of the range reflects continued Reported: ~$603M - $621M softness in Multiomics in North America and Organic Growth: 3% to 5% YoY Organic: (2%) to up 1% YoY in the capital-inten
Slide 9: Appendix
Appendix © 2026 Azenta, Inc. • All rights reserved
Slide 10: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation TOTAL AZENTA $ millions except percentages Q1 F Y 25 Q2 F Y 25 Q3 F Y 25 Q4 F Y 25 F Y 25 Q1 F Y 26 Q2 F Y 26 Revenue 147.4 143.3 143.9 159.2 593.8 148.6 144.8 GAAP gross prof it 68.8 62.8 66.4 72.3 270.3 63.7 62.0 Gross profit margin 46.7% 43.8% 46.2% 45.4% 45.5% 42.
Slide 11: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation CONTINUING OPERATIONS - SEGMENTS $ millions except percentages Q1 F Y25 Q2 F Y25 Q3 F Y25 Q4 F Y25 F Y25 Q1 F Y26 Q2 F Y26 Mult iomics Revenue 66.3 63.5 66.2 73.2 269.2 67.2 63.7 Gross prof it 29.7 26.6 26.2 31.1 113.6 27.9 25.0 Gross profit margin 44.8% 41.9% 39.6% 4
Slide 12: Net Income to Adjusted EBITDA Reconciliation
Net Income to Adjusted EBITDA Reconciliation CONTINUING OPERATIONS Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 FY25 Q1 FY26 Q2 FY26 $ millions except percentages Net income (11.0) (47.7) (48.0) 50.9 (55.8) (15.4) (160.8) (Income) Loss from discontinued operations, net of tax 3.9 27.9 47.7 0.8 80.2 10.2 3.8 Net
Slide 13: Calculation of Non-GAAP Organic Revenue
Calculation of Non-GAAP Organic Revenue CONTINUING OPERATIONS Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 FY25 Q1 FY26 Q2 FY26 Revenue 4% 5% (0%) 6% 4% 1% 1% Acquisitions/divestitures 0% 0% 0% 0% 0% 0% (1%) Currency exchange rates (0%) 1% (2%) (2%) (1%) (2%) (3%) Organic revenue 3% 6% (2%) 4% 3% (1%) (3%) Q1 FY